Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588402 | 0.90 | ALDH1A1 (0.65) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL93075 | 0.90 | ALDH1A1 (0.65) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL2244195 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL11514222 | 0.78 | ALDH1A1 (0.59) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL1066396 | 0.77 | ALDH1A1 (0.62) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL8546420 | 0.77 | ALDH1A1 (1.00) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL12948136 | 0.77 | ALDH1A1 (0.44) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL22084701 | 0.77 | ALDH1A1 (0.44) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL16736608 | 0.77 | GAA (0.58) | ALDH1A1GAAUSP2PKMHPGD | |
| SCHEMBL19308593 | 0.76 | ALDH1A1 (0.46) | ALDH1A1GAAUSP2PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129829-B2 | Methods for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129829-B2 | Methods for modulating splicing | RBM17, SNRPE, SNRPB2 | ALDH1A1 3474/4885GAA 2422/4885USP2 2227/4885 |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | ALDH1A1 3474/4885GAA 2422/4885USP2 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.